Form 4: Lantheus Holdings Executive Etienne Montagut Reports Stock Transactions

Etienne Montagut, Chief Business Officer of Lantheus Holdings, reports acquisition and disposal of common stock and stock options.

Summary

• Etienne Montagut, Chief Business Officer of Lantheus Holdings, filed a Form 4 detailing changes in beneficial ownership.
• On March 1, 2024, Montagut acquired 31,326 shares of common stock and disposed of an unspecified amount, resulting in a holding of 98,580 shares.
• These shares were acquired at $0.00, likely through vesting of restricted stock units and performance-based restricted stock units (PSUs).
• On March 4, 2024, Montagut acquired an additional 21,645 shares at $0.00 due to the vesting of relative Total Shareholder Return PSUs, bringing the total to 120,225 shares.
• Montagut also acquired 18,559 stock options with an exercise price of $64.64 on March 1, 2024, exercisable beginning March 1, 2025, and expiring on March 1, 2034.
• The reported transactions include restricted stock units vesting over three years and PSUs that cliff vest after a three-year performance period, with the ultimate award size ranging from 0% to 200% of the target based on performance.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of PSUs at 200% suggests strong performance, which is a positive signal. However, the document primarily reflects routine transactions.

Positives

• The vesting of PSUs at 200% of the target suggests strong performance relative to the set goals.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the restricted stock units and PSUs suggest continued employment and performance expectations.

Industry Context

Form 4 filings are routine disclosures for publicly traded companies and their executives, providing transparency into insider transactions. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and PSU awards are common compensation practices in the pharmaceutical and biotechnology industries, used to align executive incentives with shareholder value.
• Companies like GE Healthcare, Siemens Healthineers, and Philips Healthcare also utilize similar equity-based compensation plans for their executives.
• The vesting schedules and performance metrics associated with these awards are typically benchmarked against industry peers to ensure competitiveness and effectiveness.

Stakeholder Impact

• The vesting of PSUs at a higher-than-target level could positively impact shareholder sentiment, reflecting strong company performance.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates